Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Sep 23;67(10):2702–2712. doi: 10.1002/art.39257

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Merck Sharp & Dohme Corp. Arthritis & Rheumatology is published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

A and B, Percentages of patients in the golimumab (GLM) and placebo (PBO) groups achieving 20% improvement according to the Assessment of SpondyloArthritis international Society criteria (ASAS20) (A) and ASAS40 criteria (B) at week 16, in the full analysis set (FAS) and according to magnetic resonance imaging (MRI) status (positive or negative for the presence of sacroiliitis) and C‐reactive protein (CRP) status (objective signs of inflammation [OSI] population). Differences were derived using the stratified method described by Miettinen and Nurminen (30). C, Change from baseline in the Ankylosing Spondylitis Disease Activity Score using the CRP level (ASDAS‐C) and change from baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) response over time.